Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland
12 juin 2024 05h00 HE
|
Helsinn Healthcare S.A.
Helsinn Group and Chugai Pharma Europe sign a partnership agreement renewal to commercialize AKYNZEO® in the UK and Ireland Lugano, Switzerland – June 12, 2024 – Helsinn Group (“Helsinn”), a global...
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs
03 févr. 2023 08h00 HE
|
Helsinn
Helsinn announces publication of new data evaluating impact of NEPA (netupitant/palonosetron) on hospital costs Lugano, Switzerland, February 3, 2023 - Helsinn Group (“Helsinn”), a fully integrated...
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia
29 nov. 2022 08h00 HE
|
Helsinn Healthcare S.A.
Helsinn announces presentation on CINV trial at European Society for Medical Oncology (ESMO) Asia Lugano, Switzerland, November 29, 2022 - Helsinn Group (“Helsinn”), a fully integrated global...
Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico
16 févr. 2022 07h00 HE
|
Helsinn Healthcare S.A.
Verity Pharmaceuticals™ and Helsinn Therapeutics sign exclusive agreement for the promotion of Akynzeo® and Valchlor® in Puerto Rico Toronto, Ontario and Lugano, Switzerland, February 16, 2022 ...
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron)
02 déc. 2021 04h30 HE
|
Helsinn Healthcare S.A.
Helsinn announces European Commission approval of the liquid formulation of AKYNZEO® (fosnetupitant/palonosetron) Lugano, Switzerland, December 2, 2021 – Helsinn Group, a fully integrated, global...
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor
07 déc. 2020 08h30 HE
|
Helsinn Healthcare S.A.
Helsinn to present two posters at the San Antonio Breast Cancer Symposium (SABCS) 2020 evaluating high CINV recurrence in breast cancer patients and CINV duration as its predictor Lugano,...